Skip to content

Long-Term Debt at other companies

Savara logo
SavaraSVRA
$30.07M+1.8%
Viemed Healthcare, Inc. logo
Viemed Healthcare, Inc.VMD
$8.33M+136%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$0-100%
LivaNova logo
LivaNovaLIVN
$285.16M-48.1%
ResMed logo
ResMedRMD
$664.1M-1.3%
Insmed logo
InsmedINSM
$542.22M-50.9%

Other financials

Income statement

See full
Revenue$20.6M-8.7%
Gross profit$16.0M-1.8%
Operating income-$13.0M+11.0%
Net income-$13.7M+5.5%
EPS (diluted)-$0.33+8.3%

Balance sheet

See full
Cash & equivalents$61.0M-2.4%
Total debt$56.3M-1.2%
Total equity$45.8M-41.1%
Total assets$120.0M-20.4%

Cash flow

See full
Operating cash flow-$10.1M+23.6%
CapEx$9.0K-97.0%
Free cash flow-$10.1M+25.3%

Valuation

See full
Market cap$54.91M-43.7%
Enterprise value$50.17M-39.2%
P/S0.6×-0.5×

Profitability

See full
Gross margin75.5%+2.0pp
Operating margin-58.8%-5.8pp
Net margin-60.1%-4.4pp
FCF margin-33.2%-4.4pp

Returns & leverage

See full
Return on equity-86.2%+62.6pp
Debt / equity1.2×+0.5×
Current ratio4.9×-0.1×

Where this comes from

Reported directly by Pulmonx Corporation in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.

The official record: Pulmonx Corporation’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pulmonx Corporation's long-term debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pulmonx Corporation's long-term debt?
Pulmonx Corporation (LUNG) reported long-term debt of $37.21M in Q1 2026.
How has Pulmonx Corporation's long-term debt changed year-over-year?
Pulmonx Corporation's long-term debt increased by 26.6% year-over-year, from $29.39M to $37.21M.
What does long-term debt mean?
Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.